3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow CKD732: new trials by email Literature Review of CKD732 trials Research Report on CKD732
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury ZGN-440 sterile diluent, ZGN-440 for injectable suspension - Obesity, Over-weight | Phase 2 | Completed | Zafgen, Inc. | 14 | 2014-04-01 | 2016-07-18 |
| An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension - Obesity, Over-weight | Phase 2 | Completed | Zafgen, Inc. | 17 | 2013-06-01 | 2016-07-18 |
| An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects Beloranib, Placebo - Obesity | Phase 2 | Completed | Zafgen, Inc. | 160 | 2012-08-01 | 2016-07-14 |
Obesity (3) · Craniopharyngioma (1) · Overweight (1) · Prader-Willi Syndrome (1) · Weight Loss (1)
Zafgen, Inc. (3)
Australia (2) · United States (2)
J K Marjason, MD (1) · Jennifer Miller, MD (1)